Results 141 to 150 of about 16,340 (253)

Preparation and In Vitro Evaluation of Neutron-Activated, Theranostic Samarium-153-Labeled Microspheres for Transarterial Radioembolization of Hepatocellular Carcinoma and Liver Metastasis

open access: yesPharmaceutics, 2019
Introduction: Transarterial radioembolization (TARE) has been proven as an effective treatment for unresectable liver tumor. In this study, neutron activated, 153Sm-labeled microspheres were developed as an alternative to 90Y-labeled microspheres for ...
Yin How Wong   +4 more
doaj   +1 more source

Trans-arterial embolisation therapies for unresectable intrahepatic cholangiocarcinoma: A systematic review [PDF]

open access: yes, 2015
Background: Unresectable intrahepatic cholangiocarcinoma (ICC) portends a poor prognosis despite standard systemic treatments which confer minimal survival benefits and significant adverse effects.
Bester, L   +5 more
core   +1 more source

The Objective Response and Disease Control Rates in Patients with Liver Metastastic Breast Cancer Receiving Transarterial Radioembolization: A Meta-Analysis

open access: yesCurrent Oncology
Aim: To meta-analyze the utility of transarterial radioembolization (TARE) in patients with liver metastatic breast cancer (BC), based on the objective response rate (ORR) and disease control rate (DCR).
Natale Quartuccio   +6 more
doaj   +1 more source

Rapid predictive dosimetry for radioembolization.

open access: yesAsia Oceania journal of nuclear medicine & biology
Economics of today's busy clinical practice demand both time and cost-efficient methods of predictive dosimetry for liver radioembolisation. A rapid predictive schema adapted from the Medical Internal Radiation Dose (MIRD) method i.e., Partition Model, has been devised that can be completed within minutes.
openaire   +3 more sources

Radioembolization for hepatocellular carcinoma using TheraSphere®

open access: yesSaudi Journal of Gastroenterology, 2011
Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver. Radioembolization with yttrium-90 (Y90) microspheres is a new concept in radiation therapy for HCC. This review focuses on the indications, efficacy, side effects, and future direction of Y90 therapy, using TheraSphere® , in HCC patients.Comprehensive literature reviews ...
openaire   +3 more sources

Technical Considerations of Phosphorous-32 Bremsstrahlung SPECT Imaging after Radioembolization of Hepatic Tumors: A Clinical Assessment with a Review of Imaging Parameters [PDF]

open access: yes, 2014
Background. Bremsstrahlung (BS) imaging during radioembolization (RE) confirms the deposition of radiotracer in hepatic/ extrahepatic tumors. The aimof this study is to demonstrate 32P images and to optimize the imaging parameters.
Akhlaghpoor, Shahram   +3 more
core  

Radioembolization in Hepatocellular Carcinoma

open access: yesJournal of Liver Cancer, 2014
Radioembolization is an emerging treatment modality in patients with hepatocellular carcinoma (HCC) and is a form of brachytherapy in which intra-arterially injected Ytrrium-90 microspheres are used for internal radiation purpose. Ytrrium-90 is a high energy beta particle-emitting radioisotope.
openaire   +1 more source

Protective Embolization of the Gastroduodenal Artery with a One-HydroCoil Technique in Radioembolization Procedures [PDF]

open access: yes, 2018
Purpose: Protective occlusion of the gastroduodenal artery (GDA) is required to avoid severe adverse effects and complications in radioembolization procedures.
Ernst, C.   +7 more
core  

Toward Digital Twins for Optimal Radioembolization

open access: yesPET Clinics
Radioembolization is a localized liver cancer treatment that delivers radioactive microspheres (30 micron) to tumors via a catheter inserted in the hepatic arterial tree. The goal is to maximize therapeutic efficacy while minimizing damage to healthy liver tissue.
Nisanth Kumar Panneerselvam   +2 more
openaire   +2 more sources

Long term response on Regorafenib in non-V600E BRAF mutated colon cancer: a case report [PDF]

open access: yes, 2019
Callebout, Eduard   +7 more
core   +2 more sources

Home - About - Disclaimer - Privacy